Basic research activities focused on new advanced therapies based on several research lines:
- Cell therapies: we work on human stem cell and ocular organoids as an in vitro disease model, as a cell source of retinal cells for regenerative medicine (cell therapy), and as a tool to screen novel compounds;
- Formulations of eye drops: We have pre-clinically characterized the effect of antioxidant inorganic nanoparticleson animal models showing promising results ending up in a patent. The project was financed by the ISCIII-18 led and by the ERA-NET in Nanomedicine (AC19), a European consortium coordinated by the group.
Clinical investigations focused on a collaboration with 5 hospitals within the Ocular Pathology RETICS - Oftared network to start a phase III multicentric clinical trial that obtained a grant from the ISCIII-18, coordinated by Prof. Garcia-Arumi. Our outcome of the clinical research could improve surgical techniques, enhance post-op prognosis and visual results.

Group Leader
José García Arumí

Principal Investigator (PI)
Miguel Angel Zapata Victori, Anna Boixadear Espax, Alfredo Pueyo Ferrer, Laura Natalia Distefano, Anna Duarri Pique

Sara Martin Nalda, Miguel Angelz Arcediano Sanchez, Helena Brosa Morros, Eric Kirkegaard Biosca, Jaume Rigo Quera, Olaia Subirà Gonzalez, Randa Falah, Gianluca Fatti, Sandra Banderas Garcia, Xavier Garrell Salat, Laura Sanchez Vela, Marta Garrido Marin, Fernando Trejo Velasco

PhD Students
Helena Isla Magrané

Nursing and Technical Staff
Eva Bejar Serrano, Mireia Campius Piñas, Margarita Calduch dordal, Marta Cros Perez, Mariona Fons i Castells, Gemma Gervilla Diaz, Lidia Martin Firvida, Ferran Casals Riera








Salas A, Duarri A, Fontrodona L, Ramírez DM, Badia A, Isla-Magrané H, Ferreira-de-Souza B, Zapata MÁ, Raya Á, Veiga A, García-Arumí J
Cell therapy with hiPSC-derived RPE cells and RPCs prevents visual function loss in a rat model of retinal degeneration
Mol Ther Methods Clin Dev. 2021 Feb 10;20:688-702
DOI: 10.1016/j.omtm.2021.02.006
IF: 6.698

Helena Isla-Magrané; Anna veiga; José García-Arumí; Anna Duarri
Multiocular organoids from Human Induced Pluripotent Stem Cells Displayed Retina, Cornea, and Retinal Pigment Epithelium Lineages
Stem Cell Research and Therapy. 2021 Nov 22;12:581
DOI: 10.1186/s13287-021-02651-9
IF: 6.832

Maqueda M, Mosquera JL, García-Arumí J, Veiga A, Duarri A
Repopulation of decellularized retinas with hiPSC-derived retinal pigment epithelial and ocular progenitor cells shows cell engraftment, organization and differentiation
Biomaterials. 2021 Sep;276:121049
DOI: 10.1016/j.biomaterials.2021.121049
IF: 12.479

Zapata MÁ, Banderas García S, Sánchez-Moltalvá A, Falcó A, Otero-Romero S, Arcos G, Velazquez-Villoria D, García-Arumí J
Retinal microvascular abnormalities in patients after COVID-19 depending on disease severity
Br J Ophthalmol. 2020 Dec 16:bjophthalmol-2020-317953
DOI: 10.1136/bjophthalmol-2020-317953
IF: 4.638

Zapata MA, Burés A, Gallego-Pinazo R, Gutiérrez-Sánchez E, Oléñik A, Pastor
Prevalence of age-related macular degeneration among optometric telemedicine users in Spain: a retrospective nationwide population-based study
Graefes Arch Clin Exp Ophthalmol . 2021 Jul;259(7):1993-2003
DOI: 10.1007/s00417-021-05093-4
IF: 3.117

Red de Enfermedades Inflamatorias (RICORS)
Principal Investigator: Josep García Arumí
Agency: Instituto de Salud Carlos III
Funding: 141,350€
Period: 2022-2025

Terapia génica para la retinosis pigmentaria: prueba de concepto para el gen EYS (EYeStherapy)
Principal Investigator: Josep García Arumí, Anna Duarri
Funding: 20,000€
Period: 2022-2023

CELLUX: CeO2 Nanoparticles-assisted stem cell therapy: an innovative nanopharmaceutical approach to treat retinal degenerative diseases
Principal Investigator: Anna Duarri (European Consortium Coodinator)
Agency: Euronanomed III - Instituto de Salud Carlos III
Funding: 174,845 € (999,130€ total)
Period: 2020-2022

Phase III clinical trial of intravitreal MSV (PEI 15-007) in non-arteritic ischemic optic neuropathy (NAION)
Principal Investigator: Josep García Arumí
Agency: Instituto de Salud Carlos III
Funding: 345,950€
Period: 2019-2021

LUCIA: Determinación de las condiciones para el uso de nanoparticulas de óxido de cerlo Antioxidantes en el tratamiento de la degeneración retiniana humana
Principal Investigator: Josep García Arumí
Agency: Instituto de Salud Carlos III
Funding: 123,420 €
Period: 2019-2021

Ophthalmic topical composition with ceria nanoparticles for treating diseases of posterior segment of the eye
Priority Number: EP21382320
Priority Date: 14/09/2021
Applicants: VHIR, ICREA, ICN2

Coloured solution in particular for use in surgical methods for the treatment of the bodies of humans or animals
Priority Number: EP2827911
Priority Date: 19/03/2012
Applicants: VHIR